Paul Eckburg
Chief Tech/Sci/R&D Officer presso AN2 THERAPEUTICS, INC.
Patrimonio netto: 167 102 $ in data 31/03/2024
Profilo
Paul Eckburg is currently an Adjunct Clinical Assistant Professor at Stanford University and the Chief Medical Officer at AN2 Therapeutics, Inc. He has formerly worked as a Senior Director of Clinical Development at Cerexa, Inc., Senior Director of Medical Affairs at Kalidex Pharmaceuticals, Inc., Principal at Vicuron Pharmaceuticals LLC, Member of Safety Monitoring Board at Paratek Pharmaceuticals, Inc., Chief Medical Officer at BUGWORKS Research, Inc., Zavante Therapeutics, Inc., Geom Therapeutics, Inc., SNIPR Biome ApS, and Nexgen Biosciences, Inc. He has also served as Vice President of Clinical Development at Recida Therapeutics, Inc. and Chief Medical Officer at UTILITY therapeutics Ltd.
Dr. Eckburg holds a doctorate from Rush University and an undergraduate degree from the University of Illinois At Urbana–Champaign.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
AN2 THERAPEUTICS, INC.
0.17% | 15/03/2024 | 51 416 ( 0.17% ) | 167 102 $ | 31/03/2024 |
Posizioni attive di Paul Eckburg
| Società | Posizione | Inizio |
|---|---|---|
| AN2 THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/11/2019 |
| Stanford University | Corporate Officer/Principal | - |
Precedenti posizioni note di Paul Eckburg
| Società | Posizione | Fine |
|---|---|---|
BUGWORKS Research, Inc.
 BUGWORKS Research, Inc. Pharmaceuticals: MajorHealth Technology BUGWORKS Research, Inc. operates as a drug discovery company that discovers novel pharmaceutical assets for combating Antimicrobial Resistance (AMR). The company was founded by Santanu Datta, Anand Anandkumar and V. Balasubramanian in 2014 and is headquartered in Saratoga, CA. | Chief Tech/Sci/R&D Officer | 01/04/2021 |
Geom Therapeutics, Inc.
 Geom Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Geom Therapeutics, Inc. operates as a biotechnology company focused on the development of novel antibiotics for MDR gram-negative infections. The company is headquartered in San Francisco, CA. | Chief Tech/Sci/R&D Officer | 01/05/2019 |
UTILITY therapeutics Ltd.
 UTILITY therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections. | Chief Tech/Sci/R&D Officer | 01/05/2019 |
Recida Therapeutics, Inc.
 Recida Therapeutics, Inc. BiotechnologyHealth Technology Recida Therapeutics, Inc. engages in the development of novel therapeutics. The company was founded by Yigong Ge, Aditya Kohli, and David A. Socks in 2016 and is headquartered in Menlo Park, CA. | Chief Tech/Sci/R&D Officer | 01/05/2019 |
Zavante Therapeutics, Inc.
 Zavante Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Zavante Therapeutics, Inc. manufactures pharmaceutical products. Its product ZOLYD is an investigational, first-in-class epoxide antibiotic with a spectrum of bactericidal Gram-negative and Gram-positive activity, including activity against most contemporary MDR strains that threaten hospitalized patients. The company was founded by Cam L. Garner, Evelyn Ellis-Grosse and Theodore R. Schroeder in 2013 and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | 01/07/2018 |
Formazione di Paul Eckburg
| Rush University | Doctorate Degree |
| University of Illinois At Urbana–Champaign | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| PARATEK PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 11 |
|---|---|
Vicuron Pharmaceuticals LLC
 Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Health Technology |
Cerexa, Inc.
 Cerexa, Inc. Pharmaceuticals: MajorHealth Technology Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA. | Health Technology |
Kalidex Pharmaceuticals, Inc.
 Kalidex Pharmaceuticals, Inc. BiotechnologyHealth Technology Kalidex Pharmaceuticals, Inc. develops antibiotics for the treatment of serious infections. Its lead development candidate KPI-10 is a next-generation fluoroquinolone against a range of important gram-negative and gram-positive pathogens including multi-drug resistant strains and isolates resistant to currently available fluoroquinolones. The company was founded in 2010 by James Ge, Vernocn Jiang and George H. Talbot and is headquartered in Menlo Park, CA. | Health Technology |
BUGWORKS Research, Inc.
BUGWORKS Research, Inc. Pharmaceuticals: MajorHealth Technology BUGWORKS Research, Inc. operates as a drug discovery company that discovers novel pharmaceutical assets for combating Antimicrobial Resistance (AMR). The company was founded by Santanu Datta, Anand Anandkumar and V. Balasubramanian in 2014 and is headquartered in Saratoga, CA. | Health Technology |
Zavante Therapeutics, Inc.
Zavante Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Zavante Therapeutics, Inc. manufactures pharmaceutical products. Its product ZOLYD is an investigational, first-in-class epoxide antibiotic with a spectrum of bactericidal Gram-negative and Gram-positive activity, including activity against most contemporary MDR strains that threaten hospitalized patients. The company was founded by Cam L. Garner, Evelyn Ellis-Grosse and Theodore R. Schroeder in 2013 and is headquartered in San Diego, CA. | Health Technology |
Geom Therapeutics, Inc.
Geom Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Geom Therapeutics, Inc. operates as a biotechnology company focused on the development of novel antibiotics for MDR gram-negative infections. The company is headquartered in San Francisco, CA. | Commercial Services |
SNIPR Biome ApS
 SNIPR Biome ApS Pharmaceuticals: MajorHealth Technology SNIPR Biome ApS develops bacterial composition to provide treatment for diabetes to cancer. The company was founded by Christian Grøndal and is headquartered in Kongens Lyngby, Denmark. | Health Technology |
Recida Therapeutics, Inc.
Recida Therapeutics, Inc. BiotechnologyHealth Technology Recida Therapeutics, Inc. engages in the development of novel therapeutics. The company was founded by Yigong Ge, Aditya Kohli, and David A. Socks in 2016 and is headquartered in Menlo Park, CA. | Health Technology |
UTILITY therapeutics Ltd.
UTILITY therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections. | Health Technology |
| AN2 Therapeutics, Inc. | |
| Nexgen Biosciences, Inc. |
- Borsa valori
- Insiders
- Paul Eckburg
